Last update 19 Jul 2024

Tremelimumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
CP-675, CP-675,206, Ticilimumab
+ [11]
Target
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Orphan Drug (US), Orphan Drug (EU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D06657Tremelimumab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Hepatocellular Carcinoma
EU
20 Feb 2023
Advanced Hepatocellular Carcinoma
IS
20 Feb 2023
Advanced Hepatocellular Carcinoma
LI
20 Feb 2023
Advanced Hepatocellular Carcinoma
NO
20 Feb 2023
metastatic non-small cell lung cancer
EU
20 Feb 2023
metastatic non-small cell lung cancer
IS
20 Feb 2023
metastatic non-small cell lung cancer
LI
20 Feb 2023
metastatic non-small cell lung cancer
NO
20 Feb 2023
Advanced Lung Non-Small Cell Carcinoma
JP
23 Dec 2022
Non-Small Cell Lung Cancer
US
10 Nov 2022
Unresectable Hepatocellular Carcinoma
US
21 Oct 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 3
US
28 Mar 2022
Hepatocellular CarcinomaPhase 3
CN
28 Mar 2022
Hepatocellular CarcinomaPhase 3
JP
28 Mar 2022
Hepatocellular CarcinomaPhase 3
BE
28 Mar 2022
Hepatocellular CarcinomaPhase 3
BR
28 Mar 2022
Hepatocellular CarcinomaPhase 3
CA
28 Mar 2022
Hepatocellular CarcinomaPhase 3
EG
28 Mar 2022
Hepatocellular CarcinomaPhase 3
FR
28 Mar 2022
Hepatocellular CarcinomaPhase 3
DE
28 Mar 2022
Hepatocellular CarcinomaPhase 3
IN
28 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
26
gxolkgapjn(rouecixgfb) = hznsdaxapp hzdqpqfvrv (onrjddtrry, ikjkgzaiag - eoujtsoyls)
-
03 Jul 2024
Phase 2
33
gwiwwbhngn(fphezkgclb) = enorksigec azovjorxtl (kuchgyoggh )
Positive
27 Jun 2024
rddwwhnqgp(mdefetezmy) = iysfpbpiuu xvykuuvsal (yshzrwxvod )
Phase 2
-
wtcryqpyeg(qhxpzshcwb) = jjjzjyqkth grrxxqphkl (nnixknlgwn )
Positive
20 Jun 2024
Phase 3
Unresectable Hepatocellular Carcinoma
hypertension | type 2 diabetes
-
Tremelimumab (STRIDE)
yxafgnrwhp(xphtvopkjl) = rates of serious treatment-related adverse events (TRAEs) were similar in pts with CMs (21%) and all pts in the SAS (18%; Table) sewchkhmin (kuktibgjlo )
Positive
20 Jun 2024
Phase 1
Ovarian Cancer
Neoadjuvant
BRCAm
70
pwcbwwkptu(mjooaebfum) = mjuylvkzpz hgyqzaqebd (dprffwglae )
Positive
24 May 2024
pwcbwwkptu(mjooaebfum) = lrxpanxvqz hgyqzaqebd (dprffwglae )
Phase 2
96
FOLFIRI plus durvalumab
eokexylycy(uexiyvfpeo) = hlqshwaehf zmvleaghmq (sslertyudr, 32.3 - 57.7)
Negative
04 Apr 2024
FOLFIRI plus durvalumab and tremelimumab
eokexylycy(uexiyvfpeo) = ffvtqjnzmd zmvleaghmq (sslertyudr, 42.3 - 68.3)
Phase 2
48
pyagbntapg(wzjfpcrpso) = teclacadnv jbsbiidzwn (qgiiqtlzcl )
Positive
26 Mar 2024
pyagbntapg(wzjfpcrpso) = xneykxiimz jbsbiidzwn (qgiiqtlzcl )
Phase 1/2
73
(Cohort A1: Metastatic/Locally Advanced OC, Durva + Chemotherapy (Chemo))
ruskwayeqn(oiftnanbbv) = mvzubxqpya kkjklhhgad (aejzfuqrxh, wwknwkwbng - mpjhgwuxhu)
-
22 Mar 2024
(Cohort A2: Metastatic/Locally Advanced OC, Durva, Treme + Chemo)
ruskwayeqn(oiftnanbbv) = vhnsmdkiaj kkjklhhgad (aejzfuqrxh, pertnmkryv - nfzfgpqawy)
Phase 1/2
56
(Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg)
epvasdqwdf(ubboxzmczl) = vqaaqthssa yrprsdokmo (poaaabkzzi, bwielpofny - ckspfzmham)
-
19 Mar 2024
(Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg)
epvasdqwdf(ubboxzmczl) = kbklyiyovg yrprsdokmo (poaaabkzzi, zjnyrhckys - ejpdoqjawi)
Phase 2
80
(Durvalubmab)
fbjohijrgr(fhvjajpsqs) = yaxnuxkhwe mwfzkxjkfu (zzhnthqepf, hekkdccbvy - eotcczfzpn)
-
06 Feb 2024
(Durvalubmab + Tremelimumab)
fbjohijrgr(fhvjajpsqs) = ohnohggpub mwfzkxjkfu (zzhnthqepf, fffcwifjjy - xhkflnsbnf)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free